Clinical validation of novel RNA fusion detection for NSCLC with SOPHiA DDM™ Dx RNAtarget Technology
About
Prof Harlé presents the validation of his use of the SOPHiA DDM™ RNAtarget Technology highlighting why fusion detection is important for the hospital and how this assay fits into the current landscape of tests available to pathology labs.
Disclaimer notice: The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
on-demand webinar
Presenters
SOPHiA GENETICS
Prof. Alexander Harlé, PhD
Biologist/Professor of liquid biopsy and tumor heterogeneity group, Institut de Cancérologie de Lorraine-Alexis Vautrin